Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Gains from Sales and Divestitures (2021 - 2025)

AVITA Medical filings provide 5 years of Gains from Sales and Divestitures readings, the most recent being $109180.0 for Q4 2025.

  • On a quarterly basis, Gains from Sales and Divestitures fell 26.49% to $109180.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $109180.0, a 26.49% decrease, with the full-year FY2025 number at $109180.0, down 26.49% from a year prior.
  • Gains from Sales and Divestitures hit $109180.0 in Q4 2025 for AVITA Medical, roughly flat from $109180.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $235059.0 in Q4 2023 to a low of $14608.0 in Q1 2025.
  • Median Gains from Sales and Divestitures over the past 5 years was $105034.0 (2022), compared with a mean of $106847.9.
  • The widest YoY moves for Gains from Sales and Divestitures: up 265.28% in 2022, down 61.26% in 2022.
  • AVITA Medical's Gains from Sales and Divestitures stood at $28754.0 in 2021, then surged by 361.04% to $132568.0 in 2022, then skyrocketed by 77.31% to $235059.0 in 2023, then crashed by 36.81% to $148532.0 in 2024, then dropped by 26.49% to $109180.0 in 2025.
  • The last three reported values for Gains from Sales and Divestitures were $109180.0 (Q4 2025), $109180.0 (Q3 2025), and $76724.0 (Q2 2025) per Business Quant data.